ACC 2011: Medtronic's Resolute DES succeeds in two trials; US approval set for 2012
This article was originally published in Clinica
Executive Summary
Two major clinical studies of Resolute, Medtronic's new-generation drug-eluting stent (DES) suggest that it may be a better therapy than the firm's Endeavor DES. Data from one of the trials will back Medtronic's US approval application for the device.
You may also be interested in...
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.